Follow the people · Insider
Matthias Bodenstedt
Matthias Bodenstedt files insider transactions with the SEC as a chief financial officer of MoonLake Immunotherapeutics (MLTX). We hold 7 disclosed purchases and sales filed since 7 April 2023, 3 of them in the last 90 days.
- Files forMLTX
- Disclosed buys and sells7 in all, 3 in the last 90 days
- Last disclosure23 June 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 5 April 2023 — 22 June 2026Chief Financial Officer · MoonLake Immunotherapeutics (MLTX)25 Form 4 lines · source: SEC Form 4
Everything they disclosed
25 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 39,120 shares of MoonLake ImmunotherapeuticsSEC Form 423 June 2026Class A ordinary shares, par value $0.0001 per share · traded 22 June 2026 · filed 23 June 2026
- ▼ sold on the open market 15,082 shares of MoonLake ImmunotherapeuticsSEC Form 418 June 2026Class A ordinary shares, par value $0.0001 per share · traded 17 June 2026 · filed 18 June 2026
- ▼ sold on the open market 2,794 shares of MoonLake ImmunotherapeuticsSEC Form 418 June 2026Class A ordinary shares, par value $0.0001 per share · traded 18 June 2026 · filed 18 June 2026
- ▼ sold on the open market 13,653 shares of MoonLake ImmunotherapeuticsSEC Form 413 May 2026Class A ordinary shares, par value $0.0001 per share · traded 11 May 2026 · filed 13 May 2026
- ▼ sold on the open market 2,426 shares of MoonLake ImmunotherapeuticsSEC Form 416 April 2026Class A ordinary shares, par value $0.0001 per share · traded 14 April 2026 · filed 16 April 2026
- ▼ sold on the open market 85,870 shares of MoonLake ImmunotherapeuticsSEC Form 410 April 2026Class A ordinary shares, par value $0.0001 per share · traded 9 April 2026 · filed 10 April 2026
- ▼ sold on the open market 1,925 shares of MoonLake ImmunotherapeuticsSEC Form 410 April 2026Class A ordinary shares, par value $0.0001 per share · traded 10 April 2026 · filed 10 April 2026
- was granted 354,296 shares of MoonLake ImmunotherapeuticsSEC Form 49 January 2026Class A ordinary shares, par value $0.0001 per share · traded 7 January 2026 · filed 9 January 2026
- was granted 354,296 shares of MoonLake ImmunotherapeuticsSEC Form 49 January 2026Class A ordinary shares, par value $0.0001 per share · traded 7 January 2026 · filed 9 January 2026
- converted 8,754 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 422 December 2025Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 19 December 2025 · filed 22 December 2025
- converted 294,473 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class A ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- returned to the issuer 294,473 shares of MoonLake ImmunotherapeuticsSEC Form 422 December 2025Class C ordinary shares, par value $0.0001 per share · traded 19 December 2025 · filed 22 December 2025
- ▲ bought on the open market 10,870 shares of MoonLake ImmunotherapeuticsSEC Form 49 October 2025Class A ordinary shares, par value $0.0001 per share · traded 8 October 2025 · filed 9 October 2025
- was granted 95,763 shares of MoonLake ImmunotherapeuticsSEC Form 43 March 2025Class A ordinary shares, par value $0.0001 per share · traded 27 February 2025 · filed 3 March 2025
- ▼ sold on the open market 94,736 shares of MoonLake ImmunotherapeuticsSEC Form 421 December 2023Class A ordinary shares, par value $0.0001 per share · traded 19 December 2023 · filed 21 December 2023
- ▼ sold on the open market 5,264 shares of MoonLake ImmunotherapeuticsSEC Form 421 December 2023Class A ordinary shares, par value $0.0001 per share · traded 20 December 2023 · filed 21 December 2023
- converted 1,872 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 43 October 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 1 October 2023 · filed 3 October 2023
- converted 62,972 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class A ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- returned to the issuer 62,972 shares of MoonLake ImmunotherapeuticsSEC Form 43 October 2023Class C ordinary shares, par value $0.0001 per share · traded 1 October 2023 · filed 3 October 2023
- converted 12,212 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 47 April 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 5 April 2023 · filed 7 April 2023
- converted 4,374 shares of MoonLake Immunotherapeutics (a derivative holding)SEC Form 47 April 2023Common shares, par value CHF 0.10 per share, of MoonLake AG · traded 5 April 2023 · filed 7 April 2023
- converted 410,796 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class A ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- returned to the issuer 410,796 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class C ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- converted 147,135 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class A ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
- returned to the issuer 147,135 shares of MoonLake ImmunotherapeuticsSEC Form 47 April 2023Class C ordinary shares, par value $0.0001 per share · traded 5 April 2023 · filed 7 April 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.